Answers are grounded in this paper and cite their sources.
Background Missing values are pervasive in high-throughput proteomics data from mass spectrometry-based experiments. They can compromise statistical power and mislead downstream inference, necessitating proper imputation as a key preprocessing step. While previous efforts, such as the 2017 National Cancer Institute-Clinical Proteomic Tumor Analysis Consortium (NCI-CPTAC) DREAM Proteogenomics Challenge, established benchmarks for imputation on isobaric labeling-based data-dependent acquisition (DDA) profiles, the applicability of these strategies to the increasingly popular label-free data-independent acquisition (DIA) experiment data remains unverified. This is a critical gap, given the distinct differences in instrument settings and acquisition modes between the two experiments. Methods To address this gap, we systematically benchmarked seven individual algorithms and four ensemble strategies on label-free DIA data, using a unique dataset comprising paired label-free DIA and tandem mass tag (TMT)-DDA global proteomics profiles from 162 melanoma tumors. By leveraging the matched TMT measurements as an independent external reference, we evaluated DIA imputation accuracy under realistic conditions. Results & Conclusion Building on these benchmarking results, we introduce DreamAI2, a DIA-optimized ensemble imputation integrating complementary strategies to achieve superior performance. This study clarifies the transferability of existing imputation methods and delivers DreamAI2 as an open-source tool (https://github.com/WangLab-MSSM/DreamAI2) alongside a rigorous validation framework for future research.
No takes yet. Share an insight, caveat, or question.
Ren et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: